Skip to main content

Table 5 Summary of major studies investigating the clinical significance of ALDH1 in locally advance breast cancer

From: Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer

Study Chemotherapy No Antibody ALDH1 cutoff % positive Main results
Tanie et al. 2009[26] Paclitaxel → FEC 108 BD ≥5% 19 • ALDH1(+) but not CD44+/CD24- phenotype is associated with chemoresistance
Gong et al. 2010[27] FEC 192 Abcam ≥20% 19.8 • ALDH1 at baseline correlated with clinical response (CR/PR) and OS
Sakakibara et al. 2011[28] AC → paclitaxel 115 BD ≥5% 39 • ALDH1(+) cells in residual axillary nodes is associated with poor prognosis
Lee et al. 2011[29] AD or AC 92 BD ≥5% 13 • ALDH1(+) but not ALDH1(−) cases had high pCR
• Increase in ALDH1 after NAC is associated with poor DFS
Resetkova et al. 2009[30] Anthracycline/paclitaxel 34 BD Any 56 • Stromal but not the tumor expression of ALDH1 is prognostic in breast cancer.
Current study FEC → TAX Or TAX → FEC 119 BD ≥5% 47 • Pre NAC, ALDH1(+) is associated with poor pCR rates
• Post NAC, ALDH1(+) cells in residual primary tumor is prognostic
• Degree of chemoresistance may be different for different chemotherapy types
  1. There was consistency among most of the studies in terms of the primary antibody used and cut-off point utilization. Variation in results could be explained by the differences in study designs and/or patients’ population.
  2. AC, adriamycin (doxorubicin), cyclophosphamide; DFS, disease free survival; FEC, fluorouracil, epirubicin, cyclophosphamide; NAC, neoadjuvant chemotherapy; OS, overall survival; TAX, docetaxel.